Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature.
Publication/Presentation Date
5-1-2025
Abstract
Drug-induced liver injury (DILI) remains an active field of clinical research and investigation with more than 4700 publications appearing in 2023 relating to hepatotoxicity of all causes and injury patterns. As in years past, we have attempted to identify and summarize highlights and controversies from the past year's literature. Several new and novel therapeutic agents were approved by the US Food and Drug Administration (FDA) in 2023, a number of which were associated with significant hepatotoxicity. Updates in the diagnosis and management of DILI using causality scores as well as newer artificial intelligence-based methods were published. Details of newly established hepatotoxins as well as updated information on previously documented hepatotoxic drugs is presented. Significant updates in treatment of DILI were also included as well as reports related to global DILI registries.
Volume
48
Issue
5
First Page
455
Last Page
488
ISSN
1179-1942
Published In/Presented At
Singh, H., Kunkle, B. F., Troia, A. R., Suvarnakar, A. M., Waterman, A. C., Khin, Y., Korkmaz, S. Y., O'Connor, C. E., & Lewis, J. H. (2025). Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature. Drug safety, 48(5), 455–488. https://doi.org/10.1007/s40264-025-01514-z
Disciplines
Medicine and Health Sciences
PubMedID
39921708
Department(s)
Fellows and Residents
Document Type
Article